Enlivex Therapeutics Ltd (TA:ENLV) — Market Cap & Net Worth
Market Cap & Net Worth: Enlivex Therapeutics Ltd (ENLV)
Enlivex Therapeutics Ltd (TA:ENLV) has a market capitalization of $458.60K (ILA171.06 Million) as of May 22, 2026. Listed on the TA stock exchange, this Israel-based company holds position #30768 globally and #460 in its home market, demonstrating a -99.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enlivex Therapeutics Ltd's stock price ILA0.72 by its total outstanding shares 237381498 (237.38 Million). Analyse cash efficiency ratio of Enlivex Therapeutics Ltd to see how efficiently the company converts income to cash.
Enlivex Therapeutics Ltd Market Cap History: 2019 to 2026
Enlivex Therapeutics Ltd's market capitalization history from 2019 to 2026. Data shows change from $1.88 Billion to $458.60K (-75.34% CAGR).
Enlivex Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enlivex Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ENLV by Market Capitalization
Companies near Enlivex Therapeutics Ltd in the global market cap rankings as of May 22, 2026.
Key companies related to Enlivex Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #224 globally with a market cap of $109.25 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #410 globally with a market cap of $66.94 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #573 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #593 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #224 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.25 Billion | $430.44 |
| #410 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.94 Billion | $649.76 |
| #573 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #593 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Enlivex Therapeutics Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Enlivex Therapeutics Ltd's market cap moved from $1.88 Billion to $ 458.60K, with a yearly change of -75.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA458.60K | -99.66% |
| 2025 | ILA136.32 Million | -48.20% |
| 2024 | ILA263.16 Million | -57.46% |
| 2023 | ILA618.59 Million | -27.68% |
| 2022 | ILA855.34 Million | -24.92% |
| 2021 | ILA1.14 Billion | -36.97% |
| 2020 | ILA1.81 Billion | -3.79% |
| 2019 | ILA1.88 Billion | -- |
End of Day Market Cap According to Different Sources
On May 21st, 2026 the market cap of Enlivex Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $458.60K USD |
| MoneyControl | $458.60K USD |
| MarketWatch | $458.60K USD |
| marketcap.company | $458.60K USD |
| Reuters | $458.60K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more